BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
HR-QoL and Sexuality in Mirena Inserted Contraception Users
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 141
- Registration Number
- NCT00498784
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1280
- Registration Number
- NCT00494871
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 458
- Registration Number
- NCT00494299
BAY12-8039: 5 Days for Sinusitis vs Placebo
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 374
- Registration Number
- NCT00492024
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00492297
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1150
- Registration Number
- NCT00492986
Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 628
- Registration Number
- NCT00492635
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 804
- Registration Number
- NCT00492726
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 293
- Registration Number
- NCT00493038
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 226
- Registration Number
- NCT00492752
© Copyright 2024. All Rights Reserved by MedPath